1. Methodology
- The first step of the protocol is to select the V3 crown sequence you wish to fold in silico. For the R2 strain, the sequence for this fragment is KSIPMGPGRAFYT.
- The 3D atomic structure of the peptide corresponding to this sequence should be built in the computer's virtual space. The ICM command for this is:
buildpep "KSIPMGPGRAFYT"
or File:New:Peptide can be selected under the pull down menu
- Several parameters of the procedure are then set, including the number of search steps (length of the search), the simulation temperature, search strategy parameters including variable restraints to bias the search towards reasonable areas, energy terms, selection of different energy calculation methods, and parameters indicating how the search will be recorded such as whether to record a movie and how many intermediate scoring conformations should be recorded. All these parameters have been optimized by previous publications (see www.molsoft.com).
- The folding is then initiated with the command:
montecarlo
or File:New:Peptide can be selected under the pull down menu Molecular Mechanics:Minimize:Global
In the former case, the parameters from step 3 should be set one by one in the command line. In the latter case, checkboxes for the most commonly chosen parameters are provided in a pane before the command is executed. For convenience, the same folding ICM script utilized for this experiment and previously published experiments is shown here:

This script can be saved in a text file and run from the computer's operating system command line (usually LINUX) rapidly using the command:
icm _foldingscript
2. Secrets to Success
- The V3 loop is a constant 35 amino acids in length in almost every known strain, so the amino acid positions are numbered from 1 to 35 starting with the originating disulfide bonded cystine at 1 and terminating with the corresponding disulfide bonded cystine at 35. Since it is part of a loop, the boundaries of the crown of V3 should be carefully chosen. If too large a fragment is chosen, it is unlikely to behave as a freely flexible segment as if it were a free peptide, so the folding simulation will not correctly assess the structure. If too small a fragment is chosen, the informative tertiary structure may not form in the simulation. Our prior study showed that the fragment from position 10 to position 22 correlated with antibody bound crystallographic conformations, so this is the fragment of any V3 loop that should be chosen for folding.
- Although using the graphical user interface and pull-down menus is user-friendly, the prior successful work on peptide folding in general using ICM and V3 loop crown folding in particular used the script above, simply modifying the sequence in the buildpep line and running the above script from the command line is recommended.
3. Representative Results
The results for the R2 folding are representative of the results for any V3 loop. To evaluate the results, the project file (it will be named "newProject1.icb" from the above script) should be opened and "Molecular Mechanics, Stack, View" chosen. A table of the stack conformations will appear. The stack conformations can be visualized graphically by clicking on the Plot/Histogram icon. "Molecular Mechanics, Stack, Play " will make a movie of the stack to visually appreciate the conformational preferences uncovered by the folding. For the R2 sequence, the conformation is beta-hairpin-like as expected for V3 loops2--especially in the fragment at positions 12 to 14 where a clear β-strand preference is seen throughout the stack, and very few alpha-helical conformations are seen. Furthermore, an energy gap of almost 3 units is seen between the lowest energy conformation and the second lowest energy conformation. From an energetic point of view, this means that the structure only flickers out of the lowest energy conformation less than one percent of the time: the folding results therefore suggest that the R2 V3 crown is a rigid, rather than flexible, structure. There may be additional important structural features in the ensemble of conformations, but they are difficult to systematically appreciate.
| | JRFL | SF162_V3JRFL | SF162_V3R2 |
| 447-52D GMT50 | 15 | 0.00061 | 0.00078 |
Table 1: Relative neutralization of JRFL and R2 V3 loops in masked and unmasked settings. The data was previously reported in Cardozo T., et al. ARHR (2008) and Pinter, A., et. al J. Virol (2004). Briefly, neutralizing activity was determined with a single-cycle infectivity assay using psVs generated with the env-defective luciferase-expressing pNL4-3.Luc.R-E- plasmid pseudotyped with the JRFL Env or the SF162 V3 variants described above: SF162_V3JRFL contains the JRFL V3 loop sequence in place of the SF162 V3 loop sequence. SF162_V3R2 contains the R2 V3 loop sequence in place of the SF162 V3 loop sequence. The psVs were incubated with serial dilutions of the 447-52D mAb for 1.5 h at 37°C, and then added to CD4+CCR5+ U87 target cells plated in 96-well plates in the presence of polybrene (10 mg=mL). After 24 hrs, cells were refed with RPMI medium containing 10% FBS and 10 mg=mL polybrene, followed by an additional 24-48 h of incubation. Luciferase activity was determined 48-72 h postinfection with a microtiter plate luminometer (HARTA, Inc.) using assay reagents from Promega, Inc. Geometric mean titers for 50% neutralization (GMT50) by 447-52D were determined by interpolation from neutralization curves and are averages of at least three independent assays.